RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIODS ENDED SEPTEMBER 30, 2026

RETRACTABLE TECHNOLOGIES INC (RVP) filed an SEC Form 8-K — Other Events. Exhibit 99 RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIODS ENDED SEPTEMBER 30, 2026 LITTLE ELM, TEXAS, November 16, 2026 — Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $14.1 million for the third quarter of 2026 and an operating loss of $4

Event · Earnings
Original reporting
Published Nov 16, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RVP
Neutral
medium confidence
Mentioned
$RVP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RVPNeutralMed
01

Why it matters

Traders can update near-term expectations for RVP’s revenue quality, gross margin drivers (EasyPoint versus syringe mix), and tariff-related cost trajectory based on the quarter and nine-month figures.

02

Market read

Fresh quarterly operating loss and detailed drivers (tariffs, domestic production share, EasyPoint mix, international order uncertainty) can influence positioning ahead of the 10-Q and subsequent analyst modeling.

03

What to watch

International order timing uncertainty could reverse the positive unit-sales momentum; also, the nine-month realized gain on equity sales may mask underlying operating weakness.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Nov. 16, 2026, for the quarter ended Sept. 30, 2026

Background

The filing is an SEC 8-K furnishing results for the periods ended Sept. 30, 2026, with additional detail to be found in the company’s 10-Q filed the same day.

Company-level read

Ticker impact

$RVPNeutralMedium confidence
Context

Retractable Technologies reports Q3 2026 net sales of $14.1M and an operating loss of $4.1M, plus tariff and cost-mix drivers.

Expected impact

Likely modest pressure or choppy trading as investors weigh continued operating losses against tariff-cost mitigation and unit growth.

Evidence & confidence

The 8-K provides fresh quarterly operating results and specific drivers (tariffs, domestic production share, EasyPoint mix) that can change near-term expectations, but it does not include guidance or a clear inflection to profitability.

Market effects

Highlights ongoing margin pressure from product mix and tariffs for medical device manufacturers, with mitigation via domestic production.

Limited direct regional read-through; domestic production and Chinese sourcing are the key operational levers.

Tariff exposure and international order timing remain relevant for cross-border medical supply chains.

Counterpoint

The operating loss widened mainly due to gross margin mix, while unit sales rose sharply and tariff expenses declined versus prior periods, suggesting the cost structure could improve faster than earnings imply.

Key entities

  • Retractable Technologies, Inc.

    NYSE American-listed medical device maker reporting Q3 and nine-month 2026 results and discussing tariff mitigation and product mix.

Related articles

$NIUMed

Niu Tech (NIU) Q3 2026 Earnings Call Transcript

Niu Tech (NIU) reported Q3 2026 earnings, with total sales volume up 15.4% YoY to 534,057 units. Revenue was RMB 1.71 billion, up 1.2% YoY. China sales grew 8.6% YoY, while international sales surged 226%. Gross margin expanded to 18.0%. The company highlighted strong growth in electric motorcycles, which accounted for 56% of China sales, and strategic product launches.

$XPMedAI 8/10

XP Q3 2026 slides: asset growth strong, but margin pressure evident

XP Inc. reported Q3 2026 earnings with total client assets up 15% YoY to R$2.2T, but net margins contracted to 26.9%. Revenue grew 8% YoY to R$5.3B, while SG&A expenses rose 12% YoY. Shares fell 4.26% post-earnings. The company is diversifying revenue, with non-investment revenues now 20% of retail revenue. Management expects 10% annual top-line growth in 2027.